Loading...
•
Dec 31, 2024
Balchem Q4 2024 Earnings Report
Balchem reported record net sales and adjusted EBITDA for the fourth quarter, with year-over-year growth in all three segments.
Key Takeaways
Balchem Corporation reported strong financial results for the fourth quarter of 2024, with record net sales of $240.0 million and adjusted EBITDA of $62.8 million. The company's GAAP net earnings increased by 26.0% compared to the prior year quarter, and free cash flow was $39.8 million.
Net sales reached a record $240.0 million, a 4.9% increase year-over-year.
GAAP net earnings increased by 26.0% to $33.6 million compared to the prior year quarter.
Adjusted EBITDA reached a record $62.8 million, a 13.4% increase year-over-year.
GAAP earnings per share was $1.03, compared to $0.82 in the prior year quarter, and adjusted earnings per share was $1.13, compared to $0.95 in the prior year quarter.
Balchem
Balchem
Balchem Revenue by Segment
Revenue by Segment
Human Nutrition & Health Revenue
CapyFin.comAnimal Nutrition & Health Revenue
CapyFin.comSpecialty Products Revenue
CapyFin.com Forward Guidance
Balchem is focused on 2025 and beyond, and management is excited about the growth opportunities and believes the company is well positioned to deliver ongoing growth for shareholders.
Revenue & Expenses
Visualization of income flow from segment revenue to net income